Business overview
Emergent BioSolutions is a specialty biopharmaceutical company focused on the development, manufacture, and commercialization of medical countermeasures. Their portfolio primarily targets public health threats, including infectious diseases and chemical, biological, radiological, and nuclear (CBRN) hazards.
Valuation
Loading valuation…
Update log
| Date | News | Impact |
|---|---|---|
| 9/7/2026 | Yahoo Finance | |
| 9/3/2026 | Yahoo Finance | |
| 9/1/2026 | 8-K — Other material events · Financial statements and exhibits | |
| 9/1/2026 | EX-99.1 — Other material events · Financial statements and exhibits | |
| 8/31/2026 | Yahoo Finance | |
| 8/12/2026 | Yahoo Finance | |
| 8/11/2026 | Rating revision: Rating 3 → Rating 4 AI review | The company's recent plummet to 52-week lows following disappointing Q2 financial results indicates ongoing instability in their core business model. Given the heightened volatility and poor fiscal performance, a downgrade to a weak rating is appropriate until there is clear evidence of financial stabilization. This rating reflects the increased risk associated with the company's reliance on fluctuating government contracts. |
| 8/11/2026 | Yahoo Finance | |
| 8/8/2026 | Emergent Biosolutions Q2 Earnings Call Highlights Yahoo Finance | Yahoo Finance |
| 8/6/2026 | EX-31.2 — Period: 2026-06-30 | |
| 8/6/2026 | EX-31.1 — Period: 2026-06-30 | |
| 8/6/2026 | Yahoo Finance | |
| 8/6/2026 | EX-32.1 — Period: 2026-06-30 | |
| 8/6/2026 | EX-32.2 — Period: 2026-06-30 | |
| 8/6/2026 | 10-Q — Period: 2026-06-30 | |
| 8/5/2026 | EX-99.1 — Results of operations released · Restructuring costs · Officer / director departure or appointment · Regulation FD disclosure · Financial statements and exhibits | |
| 8/5/2026 | Yahoo Finance | |
| 8/5/2026 | Yahoo Finance | |
| 8/5/2026 | EX-99.2 — Results of operations released · Restructuring costs · Officer / director departure or appointment · Regulation FD disclosure · Financial statements and exhibits | |
| 8/5/2026 | 8-K — Results of operations released · Restructuring costs · Officer / director departure or appointment · Regulation FD disclosure · Financial statements and exhibits | |
| 8/3/2026 | Rating revision: Rating 4 → Rating 3 AI review | While Emergent BioSolutions continues to face significant structural challenges and insider selling, the recent string of government contract modifications for ACAM2000 and BAT suggests a more stabilized operational outlook. The expansion of regulatory approvals for ACAM2000 into international markets provides a modest growth catalyst that justifies moving the company from a weak rating to a speculative rating. A conservative shift is appropriate given the continued dependence on government funding and ongoing financial recovery efforts. |
| 7/22/2026 | Emergent BioSolutions Inc. will host a conference call on August 5, 2026, to discuss the company's financial results for the second quarter of 2026. | |
| 7/1/2026 | S - Sale transaction of -3,000 shares at $8.40 | |
| 6/29/2026 | Emergent BioSolutions was awarded a $52.7 million contract modification by the U.S. government to supply ACAM2000 vaccine and related materials for smallpox preparedness. | |
| 6/4/2026 | Emergent BioSolutions is partnering with Victoria’s Voice Foundation for National Naloxone Awareness Day to promote the use of NARCAN Nasal Spray in preventing opioid overdoses. | |
| 5/28/2026 | Emergent BioSolutions received a $64.5 million contract modification from the U.S. government to supply its Botulism Antitoxin (BAT) for national biodefense purposes. | |
| 5/20/2026 | Emergent BioSolutions' ACAM2000 vaccine has received approval from Singapore’s Health Sciences Authority for expanded use in preventing mpox. | |
| 5/20/2026 | Emergent BioSolutions management will participate in several upcoming investor conferences between late May and early June 2026. | |
| 5/18/2026 | Emergent BioSolutions announced that the Saudi Food and Drug Authority has approved the registration of its ACAM2000 vaccine for smallpox and mpox. | |
| 5/2/2026 | At its 2026 Annual Meeting, Emergent BioSolutions shareholders approved all management proposals, including director elections and a stock incentive plan amendment. | |
| 5/1/2026 | Degolyer Donald W (Dir) — Sell -$129,994 Insider Form 4 | S - Sale+OE transaction of -15,481 shares at $8.40 |
| 5/1/2026 | Zoon Kathryn C (Dir) — Sell -$144,453 Insider Form 4 | S - Sale+OE transaction of -17,202 shares at $8.40 |
| 5/1/2026 | Dayal Sujata Tyagi (Dir) — Sell -$115,610 Insider Form 4 | S - Sale+OE transaction of -13,761 shares at $8.40 |
| 4/30/2026 | Katkin Keith (Dir) — Sell -$128,183 Insider Form 4 | S - Sale+OE transaction of -15,481 shares at $8.28 |
| 3/4/2025 | EX-23 — Period: 2024-12-31 | |
| 3/8/2024 | EX-23 — Period: 2023-12-31 | |
| 12/11/2023 | EX-23 — Period: 2022-12-31 | |
| 7/31/2023 | MEDICAL COUNTERMEASURES (MCM) THAT CAN BE DEPLOYED IN THE EVENT OF A FILOVIRUS OUTBREAK ARE A CRUCIAL COMPONENT TO THE UNITED STATES GOVERNMENT?S (USG?S) OUTBREAK RESPONSE PLAN. BIOMEDICAL ADVANCED RESEARCH AND DEVELOPMENT AUTHORITY (BARDA) IS SEEKIN | |
| 8/30/2019 | ACAM2000, SMALLPOX (VACCINIA) VACCINE, LIVE (ACAM) | |
| 12/12/2018 | EX-23 — Financial statements and exhibits | |
| 12/12/2018 | EX-23 — Financial statements and exhibits | |
| 9/30/2016 | IGF::OT::IGF | |
| 9/16/2013 | IGF::OT::IGF | |
| 9/27/2005 | ANTHRAX THERAPEUTICS |